StockData
Rhythm Pharmaceuticals, Inc. logo

Rhythm Pharmaceuticals, Inc. (RYTM) income statement

RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30268% above fair value
$119.04+2.43 (+2.08%)

Close on Nov 18, 2026Market cap $8.20BP/E –Yield –

Rhythm Pharmaceuticals, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
89.0%
Operating margin
-83.6%
Net margin
-85.6%
Return on equity, FY2025
-244.5%

Financial strength

Current ratio
3.45
Debt to equity
1.03
Debt to assets
24.3%
Cash to current liabilities
53.1%

Valuation

P/E ratio
–
Price to sales
34.16
Price to book
79.59
Dividend yield
–

See a number that looks wrong?